Innate Pharma SA (IPHYF) Stock Statistics & Valuation Metrics
Total Valuation
Innate Pharma SA has a market cap or net worth of $157.21M. The enterprise value is $161.31M.
- Market Cap
- $157.21M
- Enterprise Value
- $161.31M
Share Statistics
Innate Pharma SA has 111,718,925 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 111,718,925
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Innate Pharma SA’s return on equity (ROE) is 2.27 and return on invested capital (ROIC) is -146.05%.
- Return on Equity (ROE)
- 2.27
- Return on Assets (ROA)
- -0.78
- Return on Invested Capital (ROIC)
- -146.05%
- Return on Capital Employed (ROCE)
- -2.20
- Revenue Per Employee
- 23.23K
- Profits Per Employee
- -409.81K
- Employee Count
- 120
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Innate Pharma SA is -2.46. Innate Pharma SA’s PEG ratio is -0.34.
- PE Ratio
- -2.46
- PS Ratio
- 113.19
- PB Ratio
- -2.91
- Price to FCF
- -2.76
- Price to Operating Cash Flow
- -2.76
- PEG Ratio
- -0.34
Income Statement
In the last 12 months, Innate Pharma SA had revenue of 2.79M and earned -49.18M in profits. Earnings per share was -0.55.
- Revenue
- 2.79M
- Gross Profit
- 2.79M
- Operating Income
- -57.36M
- Pretax Income
- -55.38M
- Net Income
- -49.18M
- EBITDA
- -55.97M
- Earnings Per Share (EPS)
- -0.55
Cash Flow
In the last 12 months, operating cash flow was -42.63M and capital expenditures -172,000, giving a free cash flow of -42.81M billion.
- Operating Cash Flow
- -42.63M
- Free Cash Flow
- -42.81M
- Free Cash Flow per Share
- -0.46
Dividends & Yields
Innate Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -36.29%
- Earnings Yield
- -40.27%
Stock Price Statistics
- Beta
- -0.41
- 52-Week Price Change
- -24.55%
- 50-Day Moving Average
- 1.59
- 200-Day Moving Average
- 1.73
- Relative Strength Index (RSI)
- 0.41
- Average Volume (3m)
- 1,000
Important Dates
Innate Pharma SA upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 17, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Innate Pharma SA as a current ratio of 1.27, with Debt / Equity ratio of -104.00%
- Current Ratio
- 1.27
- Quick Ratio
- 1.27
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 0.10
- Interest Coverage Ratio
- -18.38
Taxes
In the past 12 months, Innate Pharma SA has paid -6.21M in taxes.
- Income Tax
- -6.21M
- Effective Tax Rate
- 0.11
Enterprise Valuation
Innate Pharma SA EV to EBITDA ratio is -2.52, with an EV/FCF ratio of -3.08.
- EV to Sales
- 126.38
- EV to EBITDA
- -2.52
- EV to Free Cash Flow
- -3.08
- EV to Operating Cash Flow
- -3.09
Balance Sheet
Innate Pharma SA has $10.90M in cash and marketable securities with $20.21M in debt, giving a net cash position of -$9.31M billion.
- Cash & Marketable Securities
- $10.90M
- Total Debt
- $20.21M
- Net Cash
- -$9.31M
- Net Cash Per Share
- -$0.08
- Tangible Book Value Per Share
- -$0.43
Margins
Gross margin is 1770.35%, with operating margin of -5133.30%, and net profit margin of -4554.32%.
- Gross Margin
- 1770.35%
- Operating Margin
- -5133.30%
- Pretax Margin
- -5394.34%
- Net Profit Margin
- -4554.32%
- EBITDA Margin
- -5009.69%
- EBIT Margin
- -5133.30%
Analyst Forecast
The average price target for Innate Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -24.21%
- EPS Growth Forecast
- 1.17%